# Integra LifeSciences Holdings share price today (Integra LifeSciences Holdings Corporation, IART)

> Integra LifeSciences Holdings Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. IART · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/iart

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $13.63 (+13.5% in a year)
- P/E: 81.2×, too little history to compare yet
- Revenue (Sep 2026): $411 M (+2.3% on a year ago)
- Profit (Sep 2026): $14.9 M
- Operating margin: 6.3% (−2.7 points on a year ago)
- ROE: −50%, FY25
- ROIC: 3.4%, against a 5.7% cost of capital: −2.3 points
- Profit that came in as cash: 172%, last 3 years

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Integra LifeSciences Holdings share price today? Integra LifeSciences Holdings Corporation's share price was $13.63 at the close on 3 November 2026. That is 3.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between $9 and $20, and at that close it sat 43% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 10 weeks running. Over the last 1 year the share price moved +8% while the S&P 500 moved +21%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 28 August 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Integra LifeSciences Holdings pay? Integra LifeSciences Holdings Corporation pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Integra LifeSciences Holdings on? Integra LifeSciences Holdings is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Integra LifeSciences Holdings profitable? Integra LifeSciences Holdings Corporation earned $14.9 M of net profit in the Sep 2026 quarter. The full FY25 year was a loss of $516 M. That is 3.6% of the quarter's revenue. The same quarter a year earlier lost $5.4 M. 8 of the last 12 reported quarters were loss-making. ## How much revenue does Integra LifeSciences Holdings make, and is it growing? Integra LifeSciences Holdings Corporation reported $411 M of revenue in the Sep 2026 quarter, +2.3% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 4 years it has grown 1.5% a year on average. The last full year, FY25, came in at $1.6 B. The last four reported quarters add to $1.7 B. Recent pace: the last four quarters grew +0.9% on average, against 1.5% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +0.8%, against +2.9% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Integra LifeSciences Holdings keep? Integra LifeSciences Holdings Corporation's operating margin was 6.3% in the Sep 2026 quarter, 2.7 percentage points lower than the same quarter a year ago. Across 5 years it has been between 7.2% and 15.3%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −2.7 percentage points on the year while gross margin changed −4.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Integra LifeSciences Holdings' profit turning into cash? Over the last 3 years, 172% of Integra LifeSciences Holdings Corporation's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $50.4 M of operating cash against −$516 M of profit. After $81.4 M of spending on assets, free cash was −$31.1 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Integra LifeSciences Holdings' cash go? Integra LifeSciences Holdings Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $253 M on assets over the last 3 years. Averaged over those years that is 5.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $253 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Integra LifeSciences Holdings' P/E ratio, and how does it compare with its own history? Integra LifeSciences Holdings Corporation's P/E is 81.2×, with too little history to compare. Its usual P/E (the middle reading) is 78.7×, over 1 month of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Integra LifeSciences Holdings business getting better or worse? Integra LifeSciences Holdings Corporation's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Integra LifeSciences Holdings earn on its capital? Integra LifeSciences Holdings Corporation earned a ROE of −50% in FY25. Its return on capital used (ROIC) is 2.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −31.6% net margin and 0.45× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −31.6% net margin × 0.45× asset turnover × 3.45× leverage (assets divided by equity) ≈ −49.1% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 3.4% − 5.7% = −2.3 percentage points. The 5.7% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 3.4% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 4.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Integra LifeSciences Holdings have too much debt? Integra LifeSciences Holdings Corporation has total debt of $2.0 B against shareholder equity of $1.1 B as of Sep 2026, so its debt is 1.88× its equity. Year by year, that ratio went from 1.01 in FY21 to 1.95 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Integra LifeSciences Holdings shareholding pattern? 12.5% of Integra LifeSciences Holdings Corporation's tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 6.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Integra LifeSciences Holdings from balance-sheet trouble? For Integra LifeSciences Holdings Corporation, the Z-score is 1.36. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.36 is inside the danger zone, so the balance sheet is a real risk. ## How does Integra LifeSciences Holdings rank in its industry? There is no score against its industry: Integra LifeSciences Holdings Corporation is not among the largest members shown in this industry comparison for Medical Devices. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Integra LifeSciences Holdings compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Integra LifeSciences Holdings in size? Integra LifeSciences Holdings is the 40th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: CeriBell, Inc., Lumexa Imaging Holdings, Inc. and SI-BONE, Inc. Just below it: IRADIMED CORPORATION, QuidelOrtho Corporation and Bioventus Inc. ### Medical Devices companies close in size

1. [CeriBell, Inc.](https://www.sectoralpha.in/us/stocks/cbll) $1.1 billion
2. [Lumexa Imaging Holdings, Inc.](https://www.sectoralpha.in/us/stocks/lmri) $1.1 billion
3. [SI-BONE, Inc.](https://www.sectoralpha.in/us/stocks/sibn) $1.1 billion
4. Integra LifeSciences Holdings Corporation $1.1 billion
5. [IRADIMED CORPORATION](https://www.sectoralpha.in/us/stocks/irmd) $1 billion
6. [QuidelOrtho Corporation](https://www.sectoralpha.in/us/stocks/qdel) $966 million
7. [Bioventus Inc.](https://www.sectoralpha.in/us/stocks/bvs) $920 million

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Clarivate Plc](https://www.sectoralpha.in/us/stocks/clvt) $1.1 billion · Information Technology Services
2. [Ridgepost Capital, Inc](https://www.sectoralpha.in/us/stocks/rpc) $1.1 billion · Asset Management
3. Integra LifeSciences Holdings Corporation $1.1 billion
4. [Business First Bancshares, Inc.](https://www.sectoralpha.in/us/stocks/bfst) $1.1 billion · Banks - Regional
5. [Mercantile Bank Corporation](https://www.sectoralpha.in/us/stocks/mbwm) $1.1 billion · Banks - Regional

## What else do people ask about Integra LifeSciences Holdings? ### What were Integra LifeSciences Holdings's latest quarterly results? Integra LifeSciences Holdings Corporation reported revenue of $411 M and net profit of $14.9 M for the Sep 2026 quarter. Earnings per share were $0.19. The operating margin was 6.3%, 2.7 percentage points lower than a year earlier (as of 3 November 2026). ### What is Integra LifeSciences Holdings's market cap? Integra LifeSciences Holdings Corporation's market capitalisation is $1.1 B at a stock price of $13.63. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Integra LifeSciences Holdings performing? Integra LifeSciences Holdings Corporation's latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 10 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Integra LifeSciences Holdings's stock price go up? This page does not forecast Integra LifeSciences Holdings Corporation's stock price. What it shows instead: the stock price is $13.63. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Integra LifeSciences Holdings in its business cycle? Integra LifeSciences Holdings Corporation's FY25 operating margin was 8.9%, against a 5-year range of 7.2% to 15.3%: the low end of its own range, which is often where recoveries start. The latest quarter was 6.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Integra LifeSciences Holdings story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Integra LifeSciences Holdings a stock worth studying right now? What the numbers show: Integra LifeSciences Holdings Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.